Data Exchange Profiles for 2022 CDC Clinical Practice Guideline for Prescribing Opioids
1.0.0-ballot - STU 1 - Ballot United States of America flag

This page is part of the Data Exchange Profiles for 2022 CDC Clinical Practice Guideline for Prescribing Opioids (v1.0.0-ballot: STU 1 Ballot 1) based on FHIR (HL7® FHIR® Standard) R4. No current official version has been published yet. For a full list of available versions, see the Directory of published versions

Terminology

Page standards status: Informative

CodeSystems

CodeSystemDescription

ValueSets

ValueSetDescription
Amphetamine-class drugs and metabolite urine tests

Urine tests, both quantitative and qualitative, including confirmatory, that detect Amphetamine-class drugs and metabolites

Amphetamine class medications

Amphetamine class medications based upon the mapping of SNOMED CT drug class to ingredient then linked to RXNorm

Barbiturate Medications

All Barbiturate medications

Barbiturate urine drug screening tests

Presumed general urine tests for barbiturates that are not specific to a particular substance.

Benzodiazepine medications

All benzodiazepine clinical drugs

Benzodiazepine urine drug screening tests

Presumed general urine tests for benzodiazepines that are not specific to a particular substance.

Buprenorphine Medications

All Buprenorphine medications

Buprenorphine urine drug screening tests

Presumed general urine tests for buprenorphine.

Cannabinoid class urine drug screening

Cannabinoid, including synthetic and THC, urine tests

CDC malignant cancer conditions

All neoplastic and malignant conditions, including pain due to neoplasm.

CNS depressant medications

Medications considered to have an ingredient considered to be a CNS depressant, some of which may be mild. Removed from this set are cough medications and bowl transit modifiers.

Cocaine urine drug screening tests

Urine tests for cocaine and cocaine metabolites

Conditions likely terminal for opioid prescribing

Conditions that generally are thought to have terminal prognosis

Extended release opioid with ambulatory misuse potential

All opioid clinical drugs except those restricted to surgical use only, and that are in an extended release dose form code

Fentanyl-type medications

Fentanyl and similar medications (sufentanil, alfentanil, remifentanil)

Fentanyl-type urine drug screening tests

Urine tests for fentanyl-type drugs and metabolites

General opiate urine drug screening tests

Presumed general urine tests for naturally occurring opioids (i.e. opiates) that are not specific to a particular substance based upon the inclusion of the word 'opiates' in the long name.

Heroin urine drug screening tests

Presumed general urine tests for heroin and metabolites.

Methadone medications

Medication codes representing methadone medications

Methadone urine drug screening tests

Urine tests to identify methadone and metabolites

Naloxone medications

All naloxone medications

Non-synthetic opioid medications

Medications derived from the opium plant that are not synthetically created . All metabolize to morphine.

Opioid analgesics with ambulatory misuse potential

All opioid clinical drugs except cough medications, antispasmodics, or those restricted to surgical use only as identified by those using an injectable form.

Opioid misuse assessment procedure

Procedure to assess the risk of opioid abuse occurring by a patient

Oxycodone Medications

All Oxycodone medications

Oxycodone urine drug screening tests

Presumed general urine tests for oxycodone.

Pain management procedure

Procedure for subacute or chronic pain control management

Pain treatment plan

A Pain medicine Plan of care note

PDMP data reviewed finding

Finding indicating that the Prescription Drug Monitoring Program (PDMP) data was reviewed

PDMP review procedure

Procedure for Prescription Drug Monitoring Program (PDMP) review

Phencyclidine urine drug screening tests

Urine tests for phencyclidine

Sickle-cell diseases

Sickle-cell disorders that cause painful crisis